Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets

v3.22.2.2
Consolidated Balance Sheets - USD ($)
Aug. 31, 2022
Nov. 30, 2021
Current Assets    
Cash and cash equivalents $ 2,924,696 $ 8,263,088
Marketable securities 38,695 75,412
Accounts receivable (net of allowance for doubtful accounts of $3,326,222 and $3,078,439, respectively) 5,346,673 5,253,173
Prepaid expenses 644,846 558,413
Inventory, current portion 919,271 921,213
Other current assets 1,266,799 711,208
Total current assets 11,140,980 15,782,507
Property and Equipment-net 15,178,753 3,230,204
Other Assets    
Duke license agreement 13,931,221 14,651,802
Intangible assets, net 1,487,407 1,559,693
Inventory, net of current portion 9,394,143 9,695,363
Goodwill 1,941,411 1,941,411
Deferred tax assets 12,010,133 12,010,133
Operating lease right-of-use asset 684,668 916,493
Deposits and other assets, net 688,577 566,470
Total other assets 40,445,560 41,649,365
Total assets 66,765,293 60,662,076
Current Liabilities    
Accounts payable 1,792,650 1,489,774
Accrued expenses 2,185,088 3,057,386
Note payable 154,252 1,898,065
Dividend payable 7,672,728 0
Current portion of operating lease liability 306,404 312,067
Current portion of Duke license agreement liability 1,966,216 4,957,591
Deferred revenue 9,546,386 9,358,696
Total current liabilities 23,623,724 21,073,579
Other Liabilities    
Deferred revenue, net of current portion 34,671,785 31,274,214
Contingent consideration 987,140 727,371
Note payable, net of current portion and debt issuance costs 8,609,247 0
Operating lease long-term liability 383,943 610,989
Long-term liability - revenue sharing agreements 875,000 875,000
Total other liabilities 45,527,115 35,404,183
Total liabilities 69,150,839 56,477,762
Commitments and contingencies (Note 9) 0 0
Stockholders' (Deficit) Equity    
Preferred stock 0 0
Common stock ($.01 par value, 20,000,000 authorized; 14,848,001 issued and 8,525,255 outstanding as of August 31, 2022 and 14,665,772 issued and 8,551,816 outstanding as of November 30, 2021) 148,480 146,658
Additional paid-in capital 42,446,476 41,586,583
Treasury stock, at cost (22,505,167) (20,812,734)
Accumulated deficit (22,475,335) (16,736,193)
Total stockholders' (deficit) equity (2,385,546) 4,184,314
Total liabilities and stockholders' (deficit) equity 66,765,293 60,662,076
Series A Junior Participating Preferred Stock [Member]    
Stockholders' (Deficit) Equity    
Preferred stock 0 0
Tianhe Stem Cell Biotechnologies Inc [Member]    
Other Assets    
Investment $ 308,000 $ 308,000